16.96% to Target, RBC Capital Reconfirms “Hold” Rating for Sprint (S) Stock; 2 Analysts Are Bullish Juno Therapeutics, Inc. (JUNO) Last Week

Among 19 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 2 have Buy rating, 0 Sell and 17 Hold. Therefore 11% are positive. Juno Therapeutics Inc had 57 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of Juno Therapeutics, Inc. (NASDAQ:JUNO) has “Buy” rating given on Friday, January 29 by Suntrust Robinson. The firm earned “Buy” rating on Friday, August 5 by Maxim Group. Standpoint Research upgraded Juno Therapeutics, Inc. (NASDAQ:JUNO) on Tuesday, December 15 to “Buy” rating. The firm has “Market Perform” rating given on Tuesday, January 23 by Leerink Swann. The rating was downgraded by Barclays Capital on Wednesday, January 24 to “Equal-Weight”. On Monday, January 22 the stock rating was downgraded by Raymond James to “Hold”. The stock of Juno Therapeutics, Inc. (NASDAQ:JUNO) earned “Outperform” rating by Wells Fargo on Wednesday, February 22. On Wednesday, January 17 the stock rating was maintained by Wells Fargo with “Hold”. Needham initiated it with “Buy” rating and $65.0 target in Friday, January 5 report. The stock has “Outperform” rating by Wedbush on Tuesday, August 29. See Juno Therapeutics, Inc. (NASDAQ:JUNO) latest ratings:

24/01/2018 Broker: Standpoint Research Old Rating: Buy New Rating: Hold Downgrade
24/01/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal-Weight Downgrade
23/01/2018 Broker: Maxim Group Old Rating: Buy New Rating: Hold Downgrade
23/01/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Market Perform Old Target: $56 New Target: $87 Downgrade
23/01/2018 Broker: SunTrust Old Rating: Buy New Rating: Hold Downgrade
22/01/2018 Broker: Raymond James Rating: Hold Downgrade
22/01/2018 Broker: Needham Rating: Hold Downgrade
22/01/2018 Broker: Guggenheim Rating: Hold Downgrade
17/01/2018 Broker: Citigroup Rating: Hold New Target: $81.0 Downgrade
17/01/2018 Broker: Wedbush Rating: Hold New Target: $70.0 Downgrade

Among 28 analysts covering Sprint Nextel Corporation (NYSE:S), 4 have Buy rating, 8 Sell and 16 Hold. Therefore 14% are positive. Sprint Nextel Corporation has $32 highest and $3 lowest target. $5.51’s average target is 7.41% above currents $5.13 stock price. Sprint Nextel Corporation had 80 analyst reports since July 24, 2015 according to SRatingsIntel. The stock has “Market Perform” rating by Cowen & Co on Wednesday, August 5. Buckingham Research downgraded the stock to “Underperform” rating in Thursday, August 25 report. As per Tuesday, July 26, the company rating was upgraded by Pacific Crest. The firm earned “Neutral” rating on Thursday, October 19 by Macquarie Research. Robert W. Baird maintained the stock with “Hold” rating in Friday, February 2 report. The firm has “Hold” rating given on Monday, September 18 by Cowen & Co. The stock of Sprint Corporation (NYSE:S) has “Hold” rating given on Wednesday, August 5 by Evercore. The stock has “Hold” rating by Cowen & Co on Tuesday, July 18. FBR Capital maintained Sprint Corporation (NYSE:S) rating on Thursday, January 5. FBR Capital has “Outperform” rating and $11 target. The stock of Sprint Corporation (NYSE:S) has “Neutral” rating given on Friday, October 16 by Nomura.

Investors sentiment increased to 1.44 in Q3 2017. Its up 0.11, from 1.33 in 2017Q2. It improved, as 26 investors sold Juno Therapeutics, Inc. shares while 46 reduced holdings. 51 funds opened positions while 53 raised stakes. 66.13 million shares or 23.59% more from 53.50 million shares in 2017Q2 were reported. Glenmede Na owns 156 shares. Cormorant Asset Management Llc reported 2.97% stake. Oz Lp accumulated 12,000 shares. Vident Inv Advisory Limited Liability Corporation invested in 48,561 shares. Blackrock accumulated 0.01% or 4.53 million shares. 6.72M were reported by Vanguard Group Incorporated. Barclays Public Limited has invested 0.01% in Juno Therapeutics, Inc. (NASDAQ:JUNO). State Of Wisconsin Board invested in 0% or 12,955 shares. Wellington Shields And Com Lc accumulated 4,500 shares. Guggenheim Capital Ltd Liability Corporation invested 0.01% in Juno Therapeutics, Inc. (NASDAQ:JUNO). Macquarie Grp Inc Ltd reported 9,750 shares. Northern Tru stated it has 390,518 shares. Zurcher Kantonalbank (Zurich Cantonalbank) owns 15,792 shares for 0.01% of their portfolio. 33,445 are held by Profund Limited Liability Company. Alliancebernstein Lp has 34,020 shares for 0% of their portfolio.

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell cancer immunotherapies. The company has market cap of $9.88 billion. The firm develops cell cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. The Company’s CD19 product candidates include JCAR017 that is in Phase I/II trials for adults with relapsed or refractory B cell aggressive non-Hodgkin lymphoma (NHL) and pediatric patients with r/r B cell acute lymphoblastic leukemia (ALL); JCAR014, which is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies; and JCAR015 that is in Phase II trials for adult patients with r/r ALL.

The stock increased 0.02% or $0.02 during the last trading session, reaching $85.62. About 5.82 million shares traded or 49.16% up from the average. Juno Therapeutics, Inc. (NASDAQ:JUNO) has declined 39.85% since February 6, 2017 and is downtrending. It has underperformed by 56.55% the S&P500.

The stock decreased 4.29% or $0.23 during the last trading session, reaching $5.13. About 20.36M shares traded or 14.09% up from the average. Sprint Corporation (NYSE:S) has risen 120.49% since February 6, 2017 and is uptrending. It has outperformed by 103.79% the S&P500.

Sprint Corporation, through its subsidiaries, provides various wireless and wireline communications services and products to consumers, businesses, government subscribers, and resellers in the United States, Puerto Rico, and the U.S. The company has market cap of $20.52 billion. Virgin Islands. It has a 2.97 P/E ratio. The firm operates in two divisions, Wireless and Wireline.

Since December 13, 2017, it had 8 buys, and 1 insider sale for $207.89 million activity. 6.15M shares were bought by SOFTBANK GROUP CORP, worth $34.93 million on Friday, January 12. 144,041 shares were sold by SCHIEBER PAUL W JR, worth $827,487.

Investors sentiment decreased to 0.86 in 2017 Q3. Its down 0.20, from 1.06 in 2017Q2. It dived, as 42 investors sold Sprint Corporation shares while 95 reduced holdings. 32 funds opened positions while 86 raised stakes. 546.02 million shares or 1.36% less from 553.56 million shares in 2017Q2 were reported. Price T Rowe Associate Md reported 175,976 shares. Glenmede Tru Na stated it has 63,140 shares. Strs Ohio invested in 0.01% or 348,721 shares. Morgan Stanley reported 948,307 shares or 0% of all its holdings. Apg Asset Management Nv holds 165,300 shares or 0% of its portfolio. Pointstate Capital L P reported 0% stake. San Francisco Sentry Invest Grp (Ca) owns 63 shares. Gateway Investment Advisers Limited Liability Co holds 0.01% or 222,170 shares in its portfolio. Natixis Asset Mgmt accumulated 85,928 shares. Covington Mngmt, California-based fund reported 1,300 shares. Fiera Corp has invested 0.01% of its portfolio in Sprint Corporation (NYSE:S). The Alabama-based Andra Ap has invested 0.03% in Sprint Corporation (NYSE:S). Sumitomo Mitsui Hldg invested in 0.02% or 2.19 million shares. Commonwealth Equity accumulated 77,627 shares. 101,720 were reported by Dnb Asset Mgmt As.